PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31749144-3	2020	In this study, we aimed to assess the association between T2D, metformin use, and the risk of cancer in DM1 patients.	Metformin	63-72	immunoglobulin heavy diversity 1-7	Homo sapiens	104-107	
31749144-8	2020	DM1 patients with T2D, compared with those without T2D, were more likely to develop cancer (hazard ratio [HR]= 3.60, 95% confidence interval [CI]=1.18-10.97; p=0.02), but not if they were treated with metformin (HR=0.43, 95%CI=0.06-3.35; p=0.42).	Metformin	201-210	immunoglobulin heavy diversity 1-7	Homo sapiens	0-3	
31749144-10	2020	These results show an association between T2D and cancer risk in DM1 patients and may provide new insights into the possible benefits of Metformin use in DM1.	Metformin	137-146	immunoglobulin heavy diversity 1-7	Homo sapiens	154-157